PRECISE Study (Ovarian Cancer) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if we can identify biomarkers that indicate the presence of ovarian cancer or indicate that it is likely to develop. Biomarkers are substances that can be released from cancer cells into the blood and can provide information on the following things: changes to someone's genes or DNA, how cancer cells will respond to cancer treatment, and whether cells are becoming resistant (no longer responding) to cancer treatment.
¿Cuál es la Condición que se está estudiando?
Ovarian Cancer Detection and Risk Determination
¿Quién puede participar en el Estudio?
Women ages 18+ who:
- Are scheduled to have a risk-reducing salpingo-oophorectomy procedure to remove their fallopian tubes or a removal of an adnexal (ovarian or fallopian tube mass) as part of their regular clinical care
- Have never been treated with chemotherapy or pelvic radiation
- Are not pregnant or breastfeeding
For more information about who can join this study, please contact the study team at sarah.linhart@duke.edu.
Grupo etario
Adultos
¿Qué Implica?
If you choose to join this study, we will collect the following samples from you:
- Extracción de sangre
- Tissue samples from your fallopian tubes or an identifed mass on your fallopian tube(s) if you are scheduled to have them removed
Detalles del Estudio
Título Completo
Assessing the predictive capability of circulating tumor DNA (ctDNA) as a screening tool for ovarian cancer
Investigador Principal
Leah McNally, MD, MHS
Especialista en oncología ginecológica
Número de Protocolo
IRB:
PRO00112908
Fase
Phase
Pilot
Estado de inscripción
Abierto para inscripción